Deferoxamine alleviates brain ischemia/reperfusion injury through decreasing LAG-3 and α-Syn expression
Canadian Journal of Physiology and Pharmacology · 2026
DOI: 10.1139/cjpp-2025-0114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2026. Verfasst von Amany Mansour und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physiology, Faculty of Medicine, Aswan University, Aswan, Egypt. Hauptthemen laut MEDLINE: Reperfusion Injury, Deferoxamine, Antigens, CD, alpha-Synuclein. Die Arbeit nennt 36 Literaturangaben. Gefördert von: The Faculty of Medicine, Aswan University.
Abstract (Originalsprache)
Ischemic stroke is characterized by brain tissue iron accumulation. Alpha-synuclein (α-Syn) is a neuronal protein, its overexpression in ischemic stroke triggers apoptosis. Lymphocyte activation gene-3 (LAG-3), a receptor for α-Syn, enhances its neurotoxic effects. It is split from the cell membrane forming soluble LAG-3 (sLAG-3) in the bloodstream. The expression of LAG-3 in the brain, its relation to iron and α-Syn, as well as the association between serum sLAG-3 levels, iron, α-Syn, and stroke severity remains poorly understood. A case-control study was generated involving 24 patients with acute ischemic stroke and 24 healthy controls. In addition, an experimental study was designed involving 24 Wistar-albino rats. We randomly assigned rats to three groups: sham-operated, brain ischemia, and deferoxamine-treated ischemic rats. Ischemia decreased serum levels of iron, while increased serum levels of α-Syn and sLAG-3. Significant diagnostic performance of serum α-Syn and sLAG-3 was determined using the ROC curve (AUC = 0.962, 83.33% sensitivity, and 95.83% specificity for α-Syn; AUC = 0.755 with 62.50% sensitivity and 87.50% specificity for LAG-3). In rats, ischemia elevated brain tissue iron, α-Syn, and LAG-3 which were reduced following deferoxamine treatment. In conclusion, brain ischemia is associated with iron accumulation that promotes α-Syn expression and aggregation, potentially through increasing LAG-3 expression which improved after deferoxamine injection. In addition, this study illuminates the future beneficial targeting of LAG-3 in brain ischemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Physiology, Faculty of Medicine, Aswan University, Aswan, Egypt.
- Department of Medical Physiology, Faculty of Medicine, Assiut University, Assiut, Egypt.
- Department of Neuropsychiatry, Faculty of Medicine, Aswan University, Aswan, Egypt.
- Department of Pathology, Faculty of Medicine, Aswan University, Aswan, Egypt.
- Department of Physiology, RAK College of Medical Sciences, RAK Medical & Health Sciences University, Ras-AlKhaimah 11127, United Arab Emirates.
ORCID-Profile: Asmaa A Muhammed
Förderung
- The Faculty of Medicine, Aswan University
Zitieren
APA
Mansour, A., Abdel-Fadeil, M., Mohamed, A., Sayed, R., & Muhammed, A. (2026). Deferoxamine alleviates brain ischemia/reperfusion injury through decreasing LAG-3 and α-Syn expression. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2025-0114
Vancouver
Mansour A, Abdel-Fadeil M, Mohamed A, Sayed R, Muhammed A. Deferoxamine alleviates brain ischemia/reperfusion injury through decreasing LAG-3 and α-Syn expression. Canadian Journal of Physiology and Pharmacology. 2026. doi:10.1139/cjpp-2025-0114
BibTeX
@article{Mansour2026,
author = {Mansour, Amany and Abdel-Fadeil, Mahmoud R and Mohamed, Ahmed Shoyb and Sayed, Rasha Mohamed Samir and Muhammed, Asmaa A},
title = {Deferoxamine alleviates brain ischemia/reperfusion injury through decreasing LAG-3 and α-Syn expression},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
doi = {10.1139/cjpp-2025-0114}
}
EUVIMED